RT Journal Article
SR Electronic
T1 Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20100925
DO 10.1101/2020.05.13.20100925
A1 Sánchez-Cerrillo, Ildefonso
A1 Landete, Pedro
A1 Aldave, Beatriz
A1 Sánchez-Alonso, Santiago
A1 Azofra, Ana Sánchez
A1 Marcos-Jiménez, Ana
A1 Ávalos, Elena
A1 Alcaraz-Serna, Ana
A1 de los Santos, Ignacio
A1 Mateu-Albero, Tamara
A1 Esparcia, Laura
A1 López-Sanz, Celia
A1 Martínez-Fleta, Pedro
A1 Gabrie, Ligia
A1 del Campo Guerola, Luciana
A1 Calzada, María José
A1 González-Álvaro, Isidoro
A1 Alfranca, Arantzazu
A1 Sánchez-Madrid, Francisco
A1 Muñoz-Calleja, Cecilia
A1 Soriano, Joan B
A1 Ancochea, Julio
A1 Martín-Gayo, Enrique
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/16/2020.05.13.20100925.abstract
AB The SARS-CoV-2 is responsible for the pandemic COVID-19 in infected individuals, who can either exhibit mild symptoms or progress towards a life-threatening acute respiratory distress syndrome (ARDS). It is known that exacerbated inflammation and dysregulated immune responses involving T and myeloid cells occur in COVID-19 patients with severe clinical progression. However, the differential contribution of specific subsets of dendritic cells and monocytes to ARDS is still poorly understood. In addition, the role of CD8+ T cells present in the lung of COVID-19 patients and relevant for viral control has not been characterized. With the aim to improve the knowledge in this area, we developed a cross-sectional study, in which we have studied the frequencies and activation profiles of dendritic cells and monocytes present in the blood of COVID-19 patients with different clinical severity in comparison with healthy control individuals. Furthermore, these subpopulations and their association with antiviral effector CD8+ T cell subsets were also characterized in lung infiltrates from critical COVID-19 patients. Collectively, our results suggest that inflammatory transitional and non-classical monocytes preferentially migrate from blood to lungs in patients with severe COVID-19. CD1c+ conventional dendritic cells also followed this pattern, whereas CD141+ conventional and CD123hi plasmacytoid dendritic cells were depleted from blood but were absent in the lungs. Thus, this study increases the knowledge on the pathogenesis of COVID-19 disease and could be useful for the design of therapeutic strategies to fight SARS-CoV-2 infection.Single-sentence summary Depletion from the blood and differential activation patterns of inflammatory monocytes and CD1c+ conventional dendritic cells associate with development of ARDS in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEMG was supported by Comunidad de Madrid Talento Program (2017-T1/BMD-5396), Ramón y Cajal Program (RYC2018-024374-I), the MINECO RETOS program (RTI2018-097485-A-I00) and the NIH R21 program (R21AI140930). EMG and JBS have applied for funding for the EDEPIMIC study of COVID-19 pandemic. Grants SAF2017-82886-R to FS-M from the Ministerio de Economía y Competitividad and HR17-00016 grant from “La Caixa Banking Foundation to FS-M supported the study. AA was supported by Fondo de Investigaciones Sanitarias (FIS) PI19/00549. CMC was supported by Fondo de Investigaciones Sanitarias (FIS) PI18/01163.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNothing to declare